These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30274438)

  • 1. Recent Advances in Next Generation Snakebite Antivenoms.
    Knudsen C; Laustsen AH
    Trop Med Infect Dis; 2018 Apr; 3(2):. PubMed ID: 30274438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biosynthetic Oligoclonal Antivenom (BOA) for Snakebite and Next-Generation Treatments for Snakebite Victims.
    Kini RM; Sidhu SS; Laustsen AH
    Toxins (Basel); 2018 Dec; 10(12):. PubMed ID: 30551565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical management of snakebite envenoming: Future perspectives.
    Hamza M; Knudsen C; Gnanathasan CA; Monteiro W; Lewin MR; Laustsen AH; Habib AG
    Toxicon X; 2021 Sep; 11():100079. PubMed ID: 34430847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering and design considerations for next-generation snakebite antivenoms.
    Knudsen C; Ledsgaard L; Dehli RI; Ahmadi S; Sørensen CV; Laustsen AH
    Toxicon; 2019 Sep; 167():67-75. PubMed ID: 31173790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost of Manufacturing for Recombinant Snakebite Antivenoms.
    Jenkins TP; Laustsen AH
    Front Bioeng Biotechnol; 2020; 8():703. PubMed ID: 32766215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant snakebite antivenoms: A cost-competitive solution to a neglected tropical disease?
    Laustsen AH; Johansen KH; Engmark M; Andersen MR
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005361. PubMed ID: 28158193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guiding recombinant antivenom development by omics technologies.
    Laustsen AH
    N Biotechnol; 2018 Oct; 45():19-27. PubMed ID: 28552814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. History of Envenoming Therapy and Current Perspectives.
    Pucca MB; Cerni FA; Janke R; Bermúdez-Méndez E; Ledsgaard L; Barbosa JE; Laustsen AH
    Front Immunol; 2019; 10():1598. PubMed ID: 31354735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An interactive database for the investigation of high-density peptide microarray guided interaction patterns and antivenom cross-reactivity.
    Krause KE; Jenkins TP; Skaarup C; Engmark M; Casewell NR; Ainsworth S; Lomonte B; Fernández J; Gutiérrez JM; Lund O; Laustsen AH
    PLoS Negl Trop Dis; 2020 Jun; 14(6):e0008366. PubMed ID: 32579606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrating Engineering, Manufacturing, and Regulatory Considerations in the Development of Novel Antivenoms.
    Laustsen AH; Dorrestijn N
    Toxins (Basel); 2018 Jul; 10(8):. PubMed ID: 30065185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering of single-domain antibodies for next-generation snakebite antivenoms.
    Fernandes CFC; Pereira SS; Luiz MB; Silva NKRL; Silva MCS; Marinho ACM; Fonseca MHG; Furtado GP; Trevizani R; Nicolete R; Soares AM; Zuliani JP; Stabeli RG
    Int J Biol Macromol; 2021 Aug; 185():240-250. PubMed ID: 34118288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa.
    Williams DJ; Gutiérrez JM; Calvete JJ; Wüster W; Ratanabanangkoon K; Paiva O; Brown NI; Casewell NR; Harrison RA; Rowley PD; O'Shea M; Jensen SD; Winkel KD; Warrell DA
    J Proteomics; 2011 Aug; 74(9):1735-67. PubMed ID: 21640209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to antivenoms in the developing world: A multidisciplinary analysis.
    Potet J; Beran D; Ray N; Alcoba G; Habib AG; Iliyasu G; Waldmann B; Ralph R; Faiz MA; Monteiro WM; de Almeida Gonçalves Sachett J; di Fabio JL; Cortés MLÁ; Brown NI; Williams DJ
    Toxicon X; 2021 Nov; 12():100086. PubMed ID: 34786555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody Cross-Reactivity in Antivenom Research.
    Ledsgaard L; Jenkins TP; Davidsen K; Krause KE; Martos-Esteban A; Engmark M; Rørdam Andersen M; Lund O; Laustsen AH
    Toxins (Basel); 2018 Sep; 10(10):. PubMed ID: 30261694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toxin Neutralization Using Alternative Binding Proteins.
    Jenkins TP; Fryer T; Dehli RI; Jürgensen JA; Fuglsang-Madsen A; Føns S; Laustsen AH
    Toxins (Basel); 2019 Jan; 11(1):. PubMed ID: 30658491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovative Immunization Strategies for Antivenom Development.
    Bermúdez-Méndez E; Fuglsang-Madsen A; Føns S; Lomonte B; Gutiérrez JM; Laustsen AH
    Toxins (Basel); 2018 Nov; 10(11):. PubMed ID: 30400220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pros and cons of different therapeutic antibody formats for recombinant antivenom development.
    Laustsen AH; María Gutiérrez J; Knudsen C; Johansen KH; Bermúdez-Méndez E; Cerni FA; Jürgensen JA; Ledsgaard L; Martos-Esteban A; Øhlenschlæger M; Pus U; Andersen MR; Lomonte B; Engmark M; Pucca MB
    Toxicon; 2018 May; 146():151-175. PubMed ID: 29534892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The WHO strategy for prevention and control of snakebite envenoming: a sub-Saharan Africa plan.
    Chippaux JP; Massougbodji A; Habib AG
    J Venom Anim Toxins Incl Trop Dis; 2019; 25():e20190083. PubMed ID: 31839803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of antivenoms for snakebite envenoming in Nigeria.
    Habib AG; Lamorde M; Dalhat MM; Habib ZG; Kuznik A
    PLoS Negl Trop Dis; 2015 Jan; 9(1):e3381. PubMed ID: 25569252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phage display as a novel promising antivenom therapy: a review.
    Roncolato EC; Campos LB; Pessenda G; Costa e Silva L; Furtado GP; Barbosa JE
    Toxicon; 2015 Jan; 93():79-84. PubMed ID: 25447775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.